The virtual meeting was held on April 23-25, 2021, where J&J featured a total of 13 posters and three oral presentations, including:
Presentation #26630: The Role of Skin Barrier in Cutaneous Adverse Drug Reactions in Oncology Therapy and the Benefit of Topical Emollients;
Presentation #26634: Insights into the Mechanisms of EGFRi-induced Cutaneous Adverse Drug Reactions From Functional Phospho-proteomic and Transcriptomic Data; and
Presentation #27031: Sunscreens Designed and Validated by Consumers to be Invisible on All Skin Tones. Sun protection including sunscreen is vital for everyone to protect their skin from sun damage and help prevent skin cancer,” said Barbara Green, senior director of skin health translational science at J&J. “However, a common misconception is that Black and Brown communities do not benefit from sunscreen. We formulated products specifically to be invisible on the skin while feeling weightless and breathable. She added J&J was pleased to prese
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:01 ET | Source: Brickell Biotech, Inc. Brickell Biotech, Inc. Boulder, Colorado, UNITED STATES
Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study
- - -
- - -
Presented results from Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% & 15% at AAD VMX 2021
BOULDER, Colo., May 13, 2021 (GLOBE NEWSWIRE) Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Aveeno’s Restorative Skin Therapy Itch Relief Balm applied as needed. The anti-itch balm is formulated with prebiotic oat concentrate, aloe, pro-vitamin B5 and pramoxine HCl.
The patients reported significant improvements (
p
Share:
Extended safety analysis across eight studies helps further define the known safety profile of Olumiant 2-mg in atopic dermatitis
TORONTO, April 30, 2021 /CNW/ - Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company and Incyte s Olumiant® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate- to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, Olumiant provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by per cent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with Olumiant showed significant improvements in the severity and extent of disease comp